Unexpectedly, application of these agonists and antagonists to ganglia of naïve, uninjured animals had little effect on electrophysiological properties of DRG neurons and no effect on foot withdrawal, suggesting that sensitizing actions of these pathways in the DRG are enabled by prior injury or stress. The only effect observed in uncompressed ganglia was modest depolarization of DRG neurons by PKA and PKG agonists. CCD treatment also depolarized DRG neurons, but CCD-induced depolarization was not affected by agonists or antagonists of these pathways. 
INTRODUCTION
Injury and inflammation involving axons or somata of dorsal root ganglion (DRG) sensory neurons often cause neuropathic pain (reviewed by Devor 1994 Devor , 1999 Zimmermann 2001 ). The pain is produced in part by ectopic spontaneous activity and hyperexcitability in affected DRG neurons (Abdulla and Smith 2001a; Bennett and Xie 1988; Devor 1994; Kim and Chung 1992; Hu and Xing 1998; Ma and LaMotte 2005; Seltzer et al. 1990; Song et al. 1999 Song et al. , 2003a Stebbing et al. 1999; Wall and Gutnick 1974; Zhang et al. 1999) . Hyperexcitability may involve alterations of TTX-sensitive and TTX-resistant Na + currents (TTX-R I Na ) (Rizzo et al. 1995; Waxman 1999) , K + currents (Everill and Kocsis 1999; Yao et al. 2003) , and an N-type Ca 2+ current (Baccei and Kocsis 2000; Abdulla and Smith 2001b) , and might depend upon transcriptional changes (e.g., Costigan et al., 2002; Valder et al., 2003; Xiao et al., 2002) .
Important questions remain about the intracellular signals that induce and maintain these persistent alterations.
The cAMP-PKA pathway mediates peripheral hyperalgesic actions of inflammatory mediators (Ferreira and Nakamura 1979; Taiwo et al. 1989; Aley and Levine 1999) . In isolated DRG neurons, prostaglandin E2 (PGE 2 ) enhances soma excitability by stimulating cAMP synthesis (Hingtgen et al. 1995) and producing PKA-mediated decreases in both I k (Evans et al. 1999 ) and an after-hyperpolarization current (Fowler et al. 1985) , as well as increases in TTX-R I Na (Gold et al. 1996; England et al. 1996) , vanilloid receptor (VR-1) current (Caterina et al. 1997; Lopshire and Nicol 1998) and hyperpolarization-activated cation current (I h ) (Ingram and Williams 1994 ). An unanswered question is whether the cAMP-PKA pathway is important for neuropathic pain. Transient translocation of PKA or other PKA-dependent signals into the nucleus after nerve injury might induce long-term alterations by altering gene expression, as occurs during some forms of learning and memory (e.g., Kandel, 2001) and perhaps in the spinal 5 cord following noxious stimulation Malmberg et al., 1997; Miletic et al., 2002) .
Also, continuing activation of PKA might persistently maintain hyperalgesia and hyperexcitability (e.g., Aley and Levine, 1999; Liao et al., 1999; Bolyard et al., 2000; Aley and Levine, 2002) .
Much less attention has been paid to cGMP in studies of neuropathic pain. Although the cAMP-PKA and cGMP-PKG pathways often produce antagonistic effects, similarities between these cyclic nucleotides and between their corresponding protein kinases suggest that manipulations directed at one pathway could affect the other (e.g., Jiang et al., 1992) . Thus, some effects attributed to the cAMP-PKA pathway might involve the cGMP-PKG pathway.
Interestingly, cGMP can contribute to peripheral sensitization in DRG neurons (Aley et al., 1998) and to long-term hyperexcitability of nociceptor somata in Aplysia .
However, evidence for hyperalgesic contributions of the cGMP-PKG pathway is greater at the spinal level than in the DRG or periphery (e.g., Kress et al., 1996; Tegeder et al., 2004) , and this pathway also produces hypoalgesic effects (see Discussion).
DRG compression, which represents a significant clinical problem in humans, provides a useful animal model for investigating neuropathic pain. DRG neurons are normally electrically silent in the absence of stimulation, but after DRG compression or nerve injury 10% of DRG neurons become spontaneously active (Devor 1999; Song et al. 1999; Zhang et al. 1999 ).
Interestingly, following DRG compression, the cAMP-PKA pathway enhances spontaneous activity of large A-beta neurons (Hu et al. 2001) , which may sensitize central neurons and cause hyperalgesia (Ma and Woolf 1996; Neumann et al. 1996; Mannion et al. 1999 ).
Hyperexcitability of medium-sized (A-delta fiber) and small (C fiber) neurons also occurs (Song et al. 2003a, b; Zhang et al. 1999) . We now report that, in chronically compressed ganglia, both the cAMP-PKA and cGMP-PKG pathways help to maintain hyperalgesia and hyperexcitability 6 in DRG neurons of all sizes. Surprisingly, in uncompressed ganglia these pathways have little immediate effect on DRG neuron excitability or withdrawal behavior.
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MATERIALS AND METHODS
Surgical procedures.
Experiments were performed on adult, male Sprague-Dawley rats (n=305, 200-220 g at the start of each experiment). The rats were housed in groups of four in plastic cages (40 x 60 x 30 cm) with soft bedding and free access to food and water under a 12 hr day/12 hr night cycle. They were kept 5-7 days under these conditions, before and up to 4 weeks after surgery. All surgeries were done under sodium pentobarbital (40-50 mg/kg, i.p.) anesthesia. After surgery, the muscle and skin layers were sutured.
Hollow stainless steel rods were surgically implanted unilaterally into the intervertebral foramen (IVF) at L 4 and L 5 to chronically compress the DRG (CCD) (see Song et al. 1999 ). In brief, rats (n=48) were anesthetized, paraspinal muscles were separated from the mammillary and transverse processes and the IVF of L 4 and L 5 was exposed. A hollow, stainless-steel, L-shaped rod (4 mm in length and 0.66 mm in diameter) was implanted chronically into the IVF. In separate animals, the rod was implanted into the IVF at L 5 (n=96) or at L 5 and L 4 (n=6) and connected to silicon tubing (0.51 mm ID, 0.94 OD, 30-40 mm length, Dow Corning, Medical Materials Division) filled with saline (~10 µl). The other end of the tubing was sealed, except when injecting drugs. Unlike the solid rods used previously (Song et al. , 2003a , the hollow stainless steel rods were made from 25-gauge needles with one hole drilled on each side and one outlet on each end to permit delivery of drugs to the DRG during compression.
To deliver drugs or saline to the DRG in previously unoperated, naïve rats, a sharp, stainless steel needle, 0.4 mm in diameter (with a right angle to limit penetration), was inserted approximately 4 mm into the IVF at L 5 (n=80) after the IVF was exposed. Injections took 1.5-2 min, and the needle was then withdrawn. Each of another group of unoperated, naïve (n=6) rats received injection into the IVF at the L 5 and L4, respectively. For sham injections the needle 8 was left in the IVF for the same period of time. Sham surgery (n=8) involved identical surgical procedures to those described but without insertion of the rod or the needle.
Behavioral testing. Thermal hyperalgesia was determined by measuring foot withdrawal latency during heat stimulation (Hargreaves et al. 1988 , Song et al. 2003a . Each rat was placed in a box (22 ×12 ×12 cm) containing a smooth glass floor. The temperature of the glass was measured and maintained at 26+0.5 o C. A heat source (IITC Model 336 Analgesia Meter, Life Science, Series 8) was focused on a portion of the hindpaw that was flush against the glass, and a radiant thermal stimulus was delivered to that site. The stimulus shut off automatically when the hindpaw moved (or after 20 sec to prevent tissue damage). The intensity of the heat stimulus was maintained constant throughout all experiments. In control rats elicited paw movements occurred at a latency of 9-12 sec. Thermal stimuli were delivered 4 times to each hind paw at 5-6 min intervals. To reduce contributions from preexisting differences among individuals in thermal responsiveness, the withdrawal latencies were normalized by subtracting each value on the treated side from the corresponding value on the contralateral side and the results were expressed as difference scores. The rats were tested on each of 2 successive days prior to surgery. Postoperative tests were conducted 1, 3, 5, 7 and 10 days after surgery. Additional tests were conducted 2, 6, 12, 24 and 36 hr after injection of drugs or saline into the IVF on the third day after surgery. For the rats receiving transient needle insertion, the additional tests were conducted 6, 12, 24 and 36 hr after surgery. For the rats used for electrophysiological studies, postoperative tests were conducted 1, 3 and 5 days after surgery and on the day of electrophysiological recording (days 8-28).
Electrophysiological studies. In vitro preparations of DRGs were made from L 4 and/or L 5 ganglia for electrophysiological studies from 48 CCD, 49 naïve and another 4 sham surgery rats.
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The experimenters who performed electrophysiological recordings and analyzed data were blinded to the source of the cells. The procedure was similar to that described previously (Song et al. 2003a) . In brief, the rat was anesthetized with sodium pentobarbital after the final behavioral test. The sciatic nerve was isolated from surrounding tissue, transected at the midthigh level, and its proximal portion traced to the ganglia. A laminectomy was then performed and L 4 and L 5 DRG were identified. The location of the rod was checked immediately after exposing the ganglia. Oxygenated artificial cerebrospinal fluid (ACSF), consisting of (in mM) 130 NaCl, 3. (Anderson et al. 1987) . AP amplitude was measured from the AP threshold to the peak. AP duration was measured at threshold voltage. AHP amplitude was measured from the RMP to the peak hyperpolarization, and AHP duration was measured as the interval from onset until the AHP had recovered by 50%. Input resistance (R in ) for each neuron was obtained from the slope of the steady-state I-V relationship during a series of 100-ms hyperpolarizing currents delivered in steps of 0.1-0.2 nA from -2 to 0.5 nA. Repetitive discharge of each neuron was measured by counting the spikes evoked by intracellular injection of standardized depolarizing currents at 2.5 × threshold strength (×1000 ms). Discharge patterns of DRG neurons were classified into two groups: (1) neurons firing either one or two APs and, (2) neurons firing >2 APs (Song et al 2003a) .
Drug application. All chemicals were obtained from Sigma. Drugs were applied in the bath to excised DRG in vitro at the final concentrations indicated: the cAMP analog, 8-BrcAMP (10-500 µM); the PKA activator, Sp-cAMPS (10-500 µM); the adenylate cyclase activator, forskolin (1 µM and 10 µM); the adenylate cyclase inhibitor, SQ22536 (10-500 µM);
the PKA inhibitor, Rp-cAMPS (10-500 µM); the cGMP analog, 8-Br-cGMP (10-500 µM); the 11 PKG activator, Sp-cGMPS (10-500 µM); the guanylate cyclase inhibitor, ODQ (5 µM and 10 µM) and the PKG inhibitor, Rp-8-pCPT-cGMPS (10-500 µM). Forskolin and ODQ were dissolved in DMSO to make a 10 and 20 mM stock solution, respectively, and subsequently diluted with oxygenated ACSF prior to application. The final concentration of DMSO was 0.01-0.1%. We tested DMSO at 0.01%, 0.1% and 0.2% and found that none of these concentrations produced significant effects on the RMP or excitability of DRG neurons (data not shown).
Water soluble drugs were diluted in ACSF just before application, or diluted initially with pure water for a stock solution which was subsequently diluted with oxygenated ACSF prior to application. Application began 10-45 min prior to and continued during the 3-4 hours of electrophysiological recordings. In vivo delivery (50 µl) of antagonists (500-1000 µM) and agonists (1-500 µM) was by injection into the L 5 intervertebral foramen via silicon tubing connected to the hollow rod or through the fine needle as described above. Saline was delivered as a control. Injection was finished in about 1.5-2 min. Rats were only included in the analysis if the rod, with the tubing attached, remained within the IVF throughout the experiment.
Statistical tests. Changes in withdrawal latencies over time were tested with two-way analyses of variance (ANOVA) with repeated measures followed by Bonferroni post hoc tests.
One-way ANOVA followed by Dunnett's tests were used to test the hypothesis that RMP and excitability of DRG neurons in CCD groups were significantly different from both the naïve and sham control groups. Individual t-tests were used to test specific hypotheses about differences between each operated or drug-treated group and its corresponding control group for each electrophysiological parameter tested. Fisher's exact test (for smaller groups) and Chi-square tests (for larger groups) were used to identify differences in the incidence of effects. All data are presented as mean ± S.E.M. Unless otherwise stated, statistical results are considered significant if p < 0.05.
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RESULTS
Chronic compression produces thermal hyperalgesia
We began by confirming and extending earlier demonstrations (Hu and Xing 1998; Song et al. , 2003a Zhang et al. 1999 ) that CCD treatment produces pain and hyperalgesia. In our first study, all CCD rats used for electrophysiological analysis showed clear behavioral indications of pain and thermal hyperalgesia. Withdrawal latencies of the feet ipsilateral to CCD treatment decreased from preoperative values of 9.6±0.21 sec (mean of the two preoperative tests) to 6.2±0.31 (p<0.01, n=37) on the day of electrophysiological recordings, 1-4 weeks after treatment. Withdrawal latencies of the contralateral feet showed no significant change during the same period, going from 10.2±0.22 sec to 9.7±0.25 sec (n=37). In a second study (see Fig. 5 ), 96
additional CCD rats also showed thermal hyperalgesia. In both studies, all the CCD rats developed varying degrees of abnormality in gait and posture, which presumably serve to minimize aversive sensory stimulation . None of the naïve or sham-operated rats used in the present studies showed any significant changes in foot withdrawal responses to the radiant heat stimulation.
Chronic compression produces depolarization and hyperexcitability of DRG neuron somata
Intracellular recordings from DRG neurons were made from 236, 194 and 96 neurons of different sizes recorded from 10 CCD, 10 naïve and 4 sham surgery rats, respectively. The CCD DRG neurons, compared to those from naïve and sham ganglia, exhibited significant alterations in RMP and excitability. Although previous studies have failed to find effects of CCD treatment on RMP , Song et al. 2003a , these studies had only analyzed cells with RMP ≤ -50 mV. In the present study we noticed a shift in the distribution of RMP after CCD treatment towards the -40 to -50 mV range (Figs. 1A, B and C), and therefore set the cutoff for analysis at ≤ -40 mV. Mean RMP was significantly less negative in CCD neurons than in neurons from naïve and sham surgery animals in each size range (≤-40 mV) (p<0.01, t-test, Fig.1D ). When using a more hyperpolarized cutoff of -50 mV, significantly depolarized RMP was found in the medium-sized neurons, but not in the large or small neurons (not shown).
As previously observed ), we found that the incidence of spontaneous activity was greater in CCD ganglia (16 of 236 neurons, 6.4%) than in ganglia from sham-treated animals (2 of 96 neurons, 2%) or naïve animals (2 of 194 neurons, 1%). A neuron was defined as spontaneously active if AP discharge lasted at least 2 min after a stable recording was first obtained. All the spontaneously active neurons had RMP less negative than -55 mV (mean RMP in CCD cells, -43.7±1.1 mV, n=15).
[ Fig.1 goes here]
As found in previous studies of DRG neurons after CCD injury (Song et al. , 2003a Zhang et al. 1999) or sciatic nerve injury (Wall and Devor 1983; Devor 1994 ), significant alterations were found in the CCD neurons in AP current and voltage thresholds, patterns of repetitive discharge, and AP duration. The AP voltage thresholds decreased significantly in all sizes of CCD DRG neurons, although the difference was not statistically significant when the more depolarized cutoff of -40 mV was used (Fig.2E) . AP duration was significantly increased in medium-sized and small CCD DRG neurons with RMP cutoffs of either -40 mV or -50 mV, while that of the large neurons was increased only in the neurons with the -40 mV cutoff (Fig. 2F) . In naïve, shamoperated and CCD neurons the AP duration tended to be longer at more depolarized RMP (Fig. 2F, G) . No significant effects of CCD treatment were found on AP amplitude, AHP properties, or R in (data not shown).
[ Fig. 2 goes here]
Because neurons from sham-operated (n=96) and naïve (n=194) ganglia showed no significant differences from each other in any of the electrophysiological properties measured, and because previous studies revealed no behavioral differences between naïve and sham-treated animals at the time points tested in the present study (Hu and Xing, 1998; Song et al. 1999;  2003a), we used DRG neurons from naïve animals as controls in the following electrophysiological experiments. Changes in AP current threshold and repetitive discharge similar to the ones we find after CCD treatment have often been observed following various forms of injury to DRG neurons (Gallego et al. 1987; Gurtu and Smith 1988; Stebbing et al. 1999; Study and Kral 1996; Zhang et al. 1999; Abdulla and Smith 2001a; Song et al. 2003a,b) .
In the following studies, RMP, AP current threshold and repetitive discharge of CCD DRG neurons with RMP ≤ -40 mV were used to evaluate the effects of activators and inhibitors of the cAMP-PKA and cGMP-PKG pathways on excitability of sensory neurons after DRG compression.
The cAMP-PKA pathway contributes to compression-induced hyperexcitability
Membrane-permeant activators of PKA, 8-Br-cAMP (50 µM, n=52, 200 µM, n=48, 500 µM, n=36) and Sp-cAMPS (50 µM, n=59, 200 µM, n=51, 500 µM, n=32), significantly increased the hyperexcitability of CCD DRG neurons, as shown by a further decrease in AP current threshold and an increased incidence of repetitive discharge to depolarizing current pulses (Fig.3) . Conversely, the adenylate cyclase inhibitor, SQ22536 (50 µM, n=56, 200 µM, n=54, 500 µM, n=37), and the PKA antagonist, Rp-cAMPS (50 µM, n=63, 200 µM, n=45, 500 µM, n=47), reduced the hyperexcitability of CCD DRG neurons when applied 1-4 hrs after removal from the animal (and release of the compression). Both the facilitatory and inhibitory effects of these agents were exhibited in all sizes of CCD DRG neurons (Fig. 3) . However, neither the activators nor the inhibitors produced any change in RMP, which had already been depolarized by CCD treatment (data not shown, see also Fig. 1 ). These results indicate that activation of the cAMP-PKA pathway enhances DRG neuron excitability, and that the hyperexcitability, but not depolarization, following CCD treatment involves continuing activation of this pathway.
[ Fig.3 goes here]
The cGMP-PKG pathway contributes to compression-induced hyperexcitability
Membrane-permeant activators of PKG, 8-Br-cGMP (50 µM, n=60, 200 µM, n=44, 500 µM, n=43) and Sp-cGMPS (50 µM, n=53, 200 µM, n=56, 500 µM, n=39), significantly increased the hyperexcitability of all sizes of CCD DRG neurons, as evidenced by a further decrease in AP current threshold and an increased incidence of repetitive discharge to depolarizing current pulses (Fig. 4) . Furthermore, an inhibitor of guanylate cyclase, ODQ (5 µM, n=73, 10 µM, n=54), and an inhibitor of PKG, Rp-8-pCPT-cGMPS (50 µM, n=57, 200 µM, n=46, 500 µM, n=55) reduced the hyperexcitability of all sizes of CCD DRG neurons. Again, neither the activators nor the inhibitors of the cGMP-PKG pathway produced further changes in RMP, which had been depolarized by CCD treatment (data not shown). These results indicate that activation of the cGMP-PKG pathway can enhance DRG neuron excitability, and that the hyperexcitability, but not depolarization, following CCD treatment involves continuing activation of this pathway.
[ Given the lack of effect of activators of the cAMP-PKA and cGMP-PKG pathways on RMP in CCD neurons (above), it was a surprise to find that activation of these pathways significantly depolarized uncompressed DRG neurons from naïve rats. The mean RMP depolarized approximately 5 mV in each case (Fig.5A, p<0 . 01, t-test) . No significant differences were found among the different doses of each drug on RMP. Another surprise was that the significant effects of these pathways on RMP were associated with very little change in neuronal excitability (Fig. 5B, C) . Although the excitability of control DRG neurons tended to increase slightly, as indicated by small decreases in AP current thresholds and increases in repetitive discharge, no statistically significant differences in excitability were found between neurons treated with ACSF (n=194) and those treated for 1-4 hr with a 50-fold range of doses of the activators, 8-Br-cAMP (10 µM, n=57, 50 µM, n=63, 200 µM, n=59, 500 µM, n=48), Sp-cAMPS (10 µM, n=58, 50 µM, n=61, 200 µM, n=65, 500 µM, n=69), 8-Br-cGMP (10 µM, n=48, 50 µM, n=56, 200 µM, n=70, 500 µM, n=40), Sp-cGMPS (10 µM, n=48, 50 µM, n=53, 200 µM, n=57, 18 500 µM, n=42), as well as a 10-fold range of doses of the direct activator of adenylyl cyclase, forskolin (1 µM, n=75, 10 µM, n=71). The only exception was a significant decrease in AP threshold current in medium-sized neurons during 8-Br-cAMP treatment (Fig.5Bb) . The lack of consistent effects of a wide range of doses of PKA and PKG activators on AP threshold current and repetitive discharge to depolarizing current pulses can be seen in the dose-response relations shown in Fig.5 D and E.
[ Fig.5 goes here]
Inhibitors of cAMP-PKA and cGMP-PKG pathways failed to produce significant effects on RMP, and also failed to affect excitability in each size of DRG neuron in uncompressed ganglia from naïve rats. The RMP, AP threshold current and repetitive discharge to depolarizing test pulses exhibited no significant differences in neurons treated with ACSF compared to those treated for 1-4 hr with the inhibitors SQ22536 (10 µM, n=65, 50 µM, n=49, 200 µM, n=51, 500 µM, n=57), Rp-cAMPS (10 µM, n=66, 50 µM, n=54, 200 µM, n=62, 500 µM, n=58), ODQ (5 µM, n=67, 10 µM, n=74) or Rp-8-pCPT-cGMPS (10 µM, n=55, 50 µM, n=64, 200 µM, n=51, 500 µM, n=33). These results indicate that both the cAMP-PKA and cGMP-PKG pathways can depolarize RMP of uncompressed DRG neurons without significantly affecting excitability, and that neither pathway contributes directly to the RMP or excitability of uncompressed DRG neurons taken from naïve animals and tested in situ.
In vivo delivery of inhibitors of PKA and PKG depresses thermal hyperalgesia
Because our electrophysiological findings indicate that the cAMP-PKA and cGMP-PKG pathways are important for maintaining hyperexcitability of DRG neurons during DRG compression, and this hyperexcitability is likely to contribute to hyperalgesia, we asked whether application of blockers or agonists of these pathways alters the hyperalgesia produced by DRG compression in vivo.
The PKA inhibitor, Rp-cAMPS (0.5 mM, n=6; 1 mM, n=8), and the PKG inhibitor, Rp-8-pCPT-cGMPS (0.5 mM, n=6; 1 mM, n=8), were administered into the IVF of L 5 on the third day after injury when thermal hyperalgesia was well developed. Each inhibitor significantly interrupted the ongoing hyperalgesia, as evidenced by transient recovery of the shortened latencies of foot withdrawal (Fig. 6A ). Before surgery, there were no significant differences in the latencies of withdrawal between the left and right hind feet, and therefore the difference scores from both preoperative test sessions in each group clustered around zero. Beginning on the first postoperative day, CCD-treated rats in all groups showed profound thermal hyperalgesia, expressed as significantly reduced latency of foot withdrawal to heat stimulation on the treated side. This hyperalgesia was transiently but significantly depressed by Rp-cAMPS and by Rp-8-pCPT-cGMPS, respectively. The inhibition started within 2 hr, peaked at 6 hr and lasted about 24 hr.
Despite their enhancement of sensory neuron excitability in compressed ganglia, activators of PKA and PKG failed to enhance hyperalgesic behavior in CCD rats. The activators 8-Br-cAMP (0.1 mM, n=4; 1 mM, n=8), Sp-cAMPS (0.1 mM, n=4; 1 mM, n=8), 8-Br-cGMP (0.1 mM, n=4; 1 mM, n=8) and Sp-cGMPS (0.1 mM, n=4; 1 mM, n=8), as well as the adenylate cyclase activator forskolin (1 µM, n=6; 10 µM, n=6), did not further increase CCD-induced thermal hyperalgesia (Fig. 6B) . The lack of additional enhancement by these agonists might be due to a ceiling effect because the latencies of foot withdrawal responses after CCD treatment are very low compared to those found after other hyperalgesia-inducing treatments, including carrageenan application to the DRG, sciatic nerve constriction, and partial dorsal rhizotomy (Hu 20 and Xing, 1998; Song et al. 2003a) . The lack of effect of the agonists was not a consequence of applying the drugs to L5 only because additional experiments showed that injection of 8-BrcAMP (1 mM, n=6) into L4 as well as L5 in CCD rats again failed to augment the CCD-induced hyperalgesia (data not shown).
An interesting question is whether, in the absence of chronic compression, delivery of PKA or PKG activators to the DRG in vivo can produce thermal hyperalgesia. We attempted to answer this question by briefly inserting a fine needle into the IVF in the L5 DRG of naïve animals in order to transiently introduce the activators. No hyperalgesia was observed after sham surgery. Needle insertion by itself produced significant hyperalgesia, which started within 6-12 hr and lasted for 2-3 days in 7 rats and 5 days in one rat (see also Song et al., 1999) . Needle insertion plus injection of saline (n=8), forskolin (1 µM, n=4, 10 µM, n=4), 8-Br-cAMP (0.1 mM, n=4; 1 mM, n=4), Sp-cAMPS (0.1 mM, n=4; 1 mM, n=4), 8-Br-cGMP (0.1 mM, n=4; 1 mM, n=4) or Sp-cGMPS (0.1 mM, n=4; 1 mM, n=4) did not significantly enhance the hyperalgesia produced by needle insertion alone (Fig. 6C) . When injections were made into L4
and L5 DRG of naïve rats, 8-Br-cAMP (1 mM, n=6) injection was associated with a modest enhancement of the transient hyperalgesia compared to that induced by injection into L5 alone (peak latency difference score -2.13 ± 0.35 s versus -1.56 ± 0.27 s after injection into L5 alone).
However, this slight augmentation does not permit conclusions to be drawn about the sufficiency of agonist application to induce hyperalgesia because it might have been caused by the additional injury resulting from needle insertion into the second IVF rather than from additional agonist effects on the second DRG. The fact that the degree and duration of hyperalgesia were clearly less following needle insertion than after CCD treatment (where the peak difference scores were around -4, Fig.6C ) suggests that activation of either the PKA or PKG pathway in a DRG from naïve animals is relatively ineffective in inducing hyperalgesia.
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In contrast to the effects of PKA and PKG inhibitors in CCD rats, in naive rats neither Rp-cAMPS (0.5 mM, n=6; 1 mM, n=6) nor Rp-8-pCPT-cGMPS (0.5 mM, n=6; 1 mM, n=6) significantly altered the latencies of foot withdrawal ipsilateral or contralateral to the side of the needle insertion. Moreover, there was no significant difference between animals treated and untreated with these inhibitors (Fig. 6C) . These results indicate that application of PKA and PKG inhibitors to the DRG is not normally analgesic, but instead acts to reduce the sensitization induced by CCD treatment.
[ Fig. 6 goes here]
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DISCUSSION
The present studies indicate that both the cAMP-PKA and cGMP-PKG pathways help to maintain hyperexcitability of DRG neurons and behaviorally expressed hyperalgesia caused by DRG compression. In contrast to the effects seen in compressed ganglia, activation of either of these pathways in uncompressed ganglia from naïve animals depolarized the DRG neurons, but failed to produce significant immediate neuronal hyperexcitability or behavioral hyperalgesia.
cAMP-PKA pathway contributes to hyperexcitability in compressed ganglia
We showed previously that spontaneous activity of A-beta neurons following CCD treatment is enhanced and inhibited, respectively, by agonists and antagonists of the cAMP-PKA pathway (Hu et al., 2001) . Spontaneous activity of A-beta neurons may produce central sensitization following peripheral inflammation or nerve injury, leading to hyperalgesia or allodynia (Ma and Woolf, 1996; Neumann et al., 1996; Mannion et al., 1999; Liu et al., 2000) .
Although 90% of injured DRG neurons are silent in the absence of stimulation, many of these are hyperexcitable (Abdulla and Smith, 2001a; Ma et al., 2003; Song et al., 2003a,b; Zheng et al., 1999) . Peripheral activation of sensory neurons having hyperexcitable somata might trigger extra spikes in the somata that could contribute to sensitization and hyperalgesia (see Clatworthy and Walters, 1993; Amir et al., 2002; Gasull et al. 2005 ). Hyperexcitability of mediumsized (A-delta) and small (C) nociceptive neurons is also likely to be important for pain and hyperalgesia (e.g., Devor, 1994 Devor, , 1999 Zimmermann, 2001 ). The present results show that CCDinduced hyperexcitability of DRG neurons is reduced by antagonists of the cAMP-PKA pathway and further increased by agonists of this pathway, and that these effects occur in all sizes of DRG cells. Thus, the cAMP-PKA pathway regulates sensory neuron excitability after injury.
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Compression-induced hyperexcitability may involve changes in synthesis of ion channels (Ishikawa et al., 1999; Kim et al., 2002; Waxman, 1999; Waxman et al., 1994 Waxman et al., , 1999 Waxman et al., , 2000 Zhang et al., 1997) . However, rapid attenuation of the hyperexcitability of CCD neuron somata by application of Rp-cAMPS into the IVF indicates that it depends at least partly upon continuing activation of the cAMP-PKA pathway, as does sensitization of the sensory neurons' peripheral processes by local inflammation (Aley and Levine, 1999) . Indeed, it is possible that inflammation of the DRG is induced by the implanted rod, causing the release of inflammatory mediators such as PGE 2 that activate PKA, thus increasing the excitability of the DRG neurons by altering I k , TTX-R I Na , and I h .
cGMP-PKG pathway contributes to hyperexcitability in compressed ganglia
Our studies indicate that the cGMP-PKG pathway also contributes to hyperexcitability in compressed ganglia. A cGMP analog, 8-Br-cGMP, and a PKG agonist, Sp-cGMPS, enhanced hyperexcitability in all sizes of CCD neurons, while inhibitors of guanylate cyclase (ODQ) and of PKG (Rp-8-pCPT-cGMPS) reduced the hyperexcitability produced by CCD treatment. In principle, the enhanced excitability produced by PKG agonists might be explained by crossactivation of PKA (just as effects of PKA agonists might involve cross-activation of PKG).
However, the reduction of hyperexcitability by inhibitors that are highly selective for each pathway strongly indicates that, in the compressed DRG, both the cAMP-PKA and cGMP-PKG pathways help to maintain hyperexcitability. cGMP and PKG in the spinal cord are important for hyperalgesia (e.g., Meller and Gebhart, 1993; Niedbala et al., 1995; Salter et al., 1996; Schmidtko et al., 2003; Tegeder et al. 2004 ). However, there has been almost no evidence that this pathway operates in the DRG to produce hyperalgesia. In fact, activation of the cGMP-PKG pathway in somatic sensory neurons has often been reported to have depressive rather than sensitizing effects (e.g., Duarte et al. 1992; Kress et al. 1996; Liu et al. 2004; Sachs et al. 2004) . Different results might be accounted for by different effects of the cGMP-PKG pathway in different subsets of DRG neurons (Vivancos et al. 2003) . Evidence consistent with sensitizing effects of the cGMP-PKG pathway are observations that cGMP can increase the excitability of dissociated DRG neurons (Liu and Simon, 2003; Pollock et al., 2003) and that type 1 PKG is expressed in both developing and mature DRG neurons (Qian et al., 1996) . In addition, cGMP-PKG signaling is important for guidance and connectivity of sensory axons during development (e.g., Song et al., 1998; Schmidt et al. 2002) . Peripheral processes of adult DRG neurons are involved in some forms of hyperalgesia that depend upon peripheral NO release and local cGMP synthesis (Aley et al., 1998) . NO causes cGMP synthesis in cultured DRG neurons, but in ganglia NO-induced cGMP synthesis is suggested to occur primarily in glial cells rather than DRG neurons (e.g., Morris et al., 1992; Shi et al., 1998; Thippeswamy and Morris 2001) . However, significant levels of cGMP can be difficult to detect because of high levels of phosphodiesterase activity (e.g., Honda et al., 2001 ). An interesting possibility is that compression leads to cGMP synthesis and activation of PKG in stressed sensory axons and subsequent retrograde transport of the active PKG to neuronal somata in the DRG. This occurs in Aplysia sensory neurons after nerve injury and results in hyperexcitability of the sensory neuron soma (Sung et al. 2004 ). Potential sources of NO for stimulating cGMP synthesis in the compressed DRG and adjacent nerves include cytokines and inflammatory mediators such as bradykinin (Hess et al. 1993; Bauer et al. 1995) .
cAMP and cGMP pathways have little immediate influence on DRG neuron excitability in the absence of prior injury
Agonists and antagonists of the cAMP-PKA and cGMP-PKG pathways had little or no effect on the excitability of neurons sampled in uncompressed ganglia from naïve animals. This was true for all of the agonists and antagonists tested, across a wide range of doses. The lack of a clear effect on excitability was particularly interesting for the cAMP-PKA pathway because it appears to conflict with earlier reports. This discrepancy might reflect, in part, our relatively long delay (up to 3-4 hours) between beginning the application of agonists or antagonists and delivery of tests to DRG neurons. Previous studies utilized brief, acute applications of activators and inhibitors, and compared responses in the presence of each drug to the pre-drug baseline responses. However, the first cells we tested (within 10-45 min) showed no more evidence of hyperexcitability than did cells tested later and, of course, these agents had strong effects during the same prolonged treatment periods in compressed ganglia. Another possibility is that previous studies have examined the effects of perturbing cAMP-PKA pathways in neurons that had previously been injured by either dissociation or prior compression. The largest numbers of such studies have been performed on isolated sensory neurons in culture, which have shown that activation of the cAMP-PKA pathway enhances TTX-R I Na (England et al., 1996; Gold et al., 1996; Aley et al., 1998; Cardenas et al., 2001 ) and I h (Ingram and Williams 1996) , while depressing I K (Evans et al., 1999) . In addition, in dissociated DRG neurons this pathway enhances discharge induced by bradykinin (Cui and Nicol, 1995; Smith et al., 2000) or capsaicin (Lopshire and Nicol, 1998) , and enhances heat-induced responses by modulation of the VR-1 receptor (Caterina et al., 1997; Rathee et al., 2002) .
Interestingly, the only reports of cAMP-induced hyperexcitability in DRG neurons recorded in the ganglion have been in ganglia that had been chronically compressed (Hu et al., 2001 ). This difference indicates that, in the absence of prior injury or stress, activation of the cAMP-PKA or cGMP-PKG pathways is not sufficient to induce hyperexcitability of the DRG neuron soma, although the cAMP-PKA pathway is sufficient to induce hyperexcitability of peripheral terminals of DRG neurons (Ferreira and Nakamura 1979; Taiwo et al. 1989; Aley and Levine 1999) . It may be that these pathways are normally only linked to excitability mechanisms in the periphery (near the sensory terminals in the case of the cAMP-PKA pathway and perhaps in peripheral axons in the case of the cGMP-PKG pathway -see Sung et al. 2004 ), but nerve or ganglion injury produced by compression, inflammation, axotomy, or dissociation causes the pathways to become linked to excitability mechanisms in the soma, where they can become persistently activated to maintain soma hyperexcitability (see Aley and Levine, 1999; Liao et al., 1999; Bolyard et al., 2000; Muller 2000; Aley and Levine, 2002) . Interestingly, an "inflammatory soup" of several mediators applied to a previously compressed DRG increases the firing rate and depolarization of DRG neurons, and elicits ectopic discharge in some neurons, but these effects fail to occur in uncompressed ganglia from naïve animals (Song et al., 2003c) .
Because several of these inflammatory mediators activate the cAMP-PKA pathway to produce hyperexcitability in dissociated neuron or peripheral preparations (Cui and Nicol, 1995; Hingtgen et al., 1995; Aley and Levine, 1999; Smith et al., 2000; Southhall and Vasko, 2001 ), this result supports our conclusion that, in the absence of prior injury or stress, the cAMP-PKA pathway has no immediate effect on sensory neuron excitability.
Although they did not affect DRG neuron excitability in naïve animals, agonists of both the cAMP-PKA and cGMP-PKG pathways significantly depolarized the RMP of sensory neurons in uncompressed ganglia. CCD treatment also depolarized DRG neurons but, surprisingly, this depolarization was not altered by either agonists or antagonists of the cAMP-PKA and cGMP-PKG pathways. This indicates that both pathways can depolarize RMP under control conditions, but neither contributes significantly to RMP following CCD treatment.
Furthermore, changes in RMP produced by these pathways and by CCD treatment are relatively 27 independent of changes in neuronal excitability.
cAMP and cGMP pathways contribute to hyperalgesia produced by ganglion compression
Much evidence indicates that hyperexcitability of DRG neurons contributes to hyperalgesia in chronic pain states (Burchiel, 1984; Hu and Xing, 1998; Ji and Woolf, 2001; Kajander and Bennett, 1992; Song et al., 1999 Song et al., , 2003a Wall and Devor, 1983) . We have shown that in vivo delivery of antagonists of PKA or PKG selectively to the DRG transiently reduces compression-induced hyperalgesia as monitored by changes in foot withdrawal latency.
Therefore, ongoing activity in these signaling pathways contributes to behavioral hyperalgesia after CCD treatment.
In contrast to the in vivo effects of antagonists, the agonists delivered in vivo did not significantly alter compression-induced hyperalgesia. This might have resulted from 1) a ceiling effect, because the latency of foot withdrawal had already approached its minimum, 2) excessive hyperexcitability of DRG neurons leading to suppressive effects (e.g., excessive depolarization could decrease repetitive firing by inactivating Na + channels), or 3) inadvertent effects on other systems that opposed the behavioral effects expected from DRG neurons. Despite the lack of additional hyperalgesia produced by in vivo application of agonists, the marked inhibition of behavioral hyperalgesia by in vivo delivery of PKA and PKG antagonists provides strong evidence that the maintenance by these pathways of DRG neuron hyperexcitability in CCDtreated animals is important for behaviorally expressed hyperalgesia.
In the absence of DRG compression, in vivo delivery of agonists of the cAMP-PKA and cGMP-PKG pathways failed to produce significant hyperalgesia. Although interpretation of this result is complicated by the fact that transient insertion of the needle necessary to deliver the 28 drugs to the uncompressed ganglion caused some hyperalgesia by itself (which might occlude agonist-induced hyperalgesia), the apparent lack of agonist-induced hyperalgesia is consistent with the lack of any effects on neuronal excitability we found for these pathways in uncompressed ganglia. This reinforces our conclusion that prior injury or inflammation enables or enhances the effects of these signaling pathways on sensory neuron excitability. produced by chronic compression, but agonists of these pathways fail to enhance hyperalgesia.
A: The PKA inhibitor Rp-cAMPS (0.5 mM, n=6; 1 mM, n=8) and the PKG inhibitor Rp-8-pCPT-cGMPS (0.5 mM, n=6; 1 mM, n=8) administered on the third day after injury significantly increased foot withdrawal latencies that had been shortened by ipsilateral CCD treatment.
Significant effects started within 6 hr and lasted for 24-36 hr. Delivery of saline into the IVF did not significantly affect thermal hyperalgesia. Sham surgery did not produce hyperalgesia. B:
The PKA activators 8-Br-cAMP (0.1 mM, n=4; 1 mM, n=8), Sp-cAMPS (0.1 mM, n=4; 1 mM, n=8), the PKG activators 8-Br-cGMP (0.1 mM, n=4; 1 mM, n=8), Sp-cGMPS (0.1 mM, n=4; 1 mM, n=8), and the adenylate cyclase activator forskolin (1 µM, n=6; 10 µM, n=6) did not further increase thermal hyperalgesia. C: Needle insertion (NI) into the IVF with or without saline injection induced weak, transient hyperalgesia, but PKA activators 8-Br-cAMP (0.1 mM, n=4; 1 mM, n=8), Sp-cAMPS (0.1 mM, n=4; 1 mM, n=8), PKG activators 8-Br-cGMP (0.1 mM, n=4; 1 mM, n=8), Sp-cGMPS (0.1 mM, n=4; 1 mM, n=8), and the adenylate cyclase activator forskolin
(1 µM, n=6; 10 µM, n=6) injected through the needle failed to enhance the hyperalgesia induced by NI. The PKA antagonist Rp-cAMPS (0.5 mM, n=6; 1 mM, n=6) and the PKG antagonist Rp-8-pCPT-cGMPS (0.5 mM, n=6; 1 mM, n=6) injected through the needle inhibit neither the normal pain sensation nor the transient hyperalgesia induced by NI. Injection was made on the day of surgery (day 0). *p<0.05, **p<0.01 (Two-way ANOVA with repeated measures followed by Bonferroni post hoc tests). % of Control (AP current Threshold) Forskolin (20, 19, 14, 23, 24, 22, 15, 19, 17, 18) Forskolin (29, 28, 20, 25, 26, 19) 8-Br-cGMP (22, 20, 12, 18, 15, 14) h: Small Neurons 
